MARKET

AXDX

AXDX

Accelerate Diagnostics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5550
+0.0064
+1.17%
After Hours: 0.5550 0 0.00% 16:00 05/26 EDT
OPEN
0.5500
PREV CLOSE
0.5486
HIGH
0.5748
LOW
0.5325
VOLUME
699.42K
TURNOVER
0
52 WEEK HIGH
9.36
52 WEEK LOW
0.5020
MARKET CAP
44.09M
P/E (TTM)
-0.5256
1D
5D
1M
3M
1Y
5Y
Accelerate Diagnostics to Participate in 42nd Annual William Blair Growth Stock Conference on June 7, 2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 7, 2022, at 10:00 AM Central Time.
PR Newswire · 3d ago
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/16 22:15
Recap: Accelerate Diagnostics Q1 Earnings
Accelerate Diagnostics (NASDAQ:AXDX) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 05/16 21:43
Accelerate Diagnostics Q1 EPS $(0.25) Beats $(0.30) Estimate, Sales $2.96M Beat $2.95M Estimate
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 16.67 percent. This is a 39.02 percent increase over losses of $(0.41) per share
Benzinga · 05/16 20:44
Accelerate Diagnostics GAAP EPS of -$0.21 beats by $0.09, revenue of $2.96M beats by $0.01M
Accelerate Diagnostics press release (NASDAQ:AXDX): Q1 GAAP EPS of -$0.21 beats by $0.09. Revenue of $2.96M (+18.4% Y/Y) beats by $0.01M.
Seekingalpha · 05/16 20:16
Stocks That Hit 52-Week Lows On Monday
  On Monday, 198 companies reached new 52-week lows.
Benzinga · 05/16 17:59
-- Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Reports Q1 Revenue $3M
MT Newswires · 05/16 16:22
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 05/16 13:39
More
No Data
Learn about the latest financial forecast of AXDX. Analyze the recent business situations of Accelerate Diagnostics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
0.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AXDX stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
High1.000
Average1.000
Low1.000
Current 0.5550
EPS
Actual
Estimate
-0.29-0.22-0.14-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 156
Institutional Holdings: 28.17M
% Owned: 35.46%
Shares Outstanding: 79.44M
TypeInstitutionsShares
Increased
46
2.49M
New
14
413.98K
Decreased
24
1.78M
Sold Out
14
1.25M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.61%
Healthcare Equipment & Supplies
+0.56%
Key Executives
Non-Executive Chairman/Independent Director
John Patience
President/Chief Executive Officer/Director
John Phillips
Chief Financial Officer
Steve Reichling
Other
Ron Price
Director
Wayne Burris
Independent Director
Thomas Brown
Independent Director
Louise Francesconi
Independent Director
Hany Massarany
Independent Director
Mark Miller
Independent Director
Jack Schuler
Independent Director
Matthew Strobeck
Independent Director
Frank Ten Brink
Independent Director
Charles Watts
No Data
No Data
About AXDX
Accelerate Diagnostics, Inc. is an vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.

Webull offers kinds of Accelerate Diagnostics Inc stock information, including NASDAQ:AXDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXDX stock methods without spending real money on the virtual paper trading platform.